BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:FT819 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of FT819\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06308978-5437@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:FT819: Phase 1 readout est. (NCT06308978)
DESCRIPTION:FT819\, phase 1\, Systemic Lupus Erythematosus.\nStudy: A Phase
  1 Study of FT819 in B-cell Mediated Autoimmune Disease\nEstimated primary
  completion: 30 September 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ft819#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06308978
URL:https://assetmemo.bio/drug/ft819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07570862-5437@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:FT819: Phase 2 readout est. (NCT07570862)
DESCRIPTION:FT819\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A Phase
  2\, Open-Label\, Single-Arm Trial of FT819 in Participants With Lupus Nep
 hritis\nEstimated primary completion: 1 July 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ft819#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07570862
URL:https://assetmemo.bio/drug/ft819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
